Company: MDCXW
Filing Date: 2025-06-03
Form Type: 253G2
Source: 0001062993-25-010733
Chunk: 4

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-03
Form: 253G2
Chunk 4
---
 $1,250,000, in connection with the filing of the Company's Registration Statement on May 27, 2025, for additional net proceeds to the Company of $1,125,000.

Item 9.01.Financial Statements and Exhibits. (d) Exhibits.

| Exhibit 
 No.     
 1.1*    
 4.1     |     | Description                                                                                                                                                                                                                                       
 Placement Agency Agreement, dated as of May 29, 2025, by and between Medicus Pharma Ltd. and Maxim Group LLC as representative of the placement agents named therein                                                                              
 Form of Subscription Agreement (incorporated by reference from Exhibit 4.8 to the Company's Registration Statement on Form S-1, filed with the SEC on May 27, 2025)                                                                               |
|:--------|:----|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.2*    |     | Common Share Purchase Warrant                                                                                                                                                                                                                     |
| 4.3*

#   |     | Warrant Agency Agreement, dated as of June 2, 2025, by and between Medicus Pharma Ltd. and Odyssey Transfer and Trust Company, as warrant agent                                                                                                   |
| 99.1    |     | Pricing Press Release, dated May 29, 2025                                                                                                                                                                                                         |
| 99.2    |     | Closing Press Release, dated June 2, 2025                                                                                                                                                                                                         |
| 104.1   |     | Cover Page Interactive Data File (embedded within the inline XBRL document).                                                                                                                                                                      |
| *       |     | Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request. |
| 

#       |     | Certain schedules and exhibits have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.                     |
2

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include, but are not limited